Pyxis Oncology, Inc. $PYXS Shares Bought by 683 Capital Management LLC

683 Capital Management LLC raised its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 69.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 891,910 shares of the company’s stock after acquiring an additional 366,910 shares during the quarter. 683 Capital Management LLC owned 1.43% of Pyxis Oncology worth $1,026,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Laurion Capital Management LP lifted its holdings in Pyxis Oncology by 32.3% in the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after acquiring an additional 1,170,505 shares during the last quarter. ExodusPoint Capital Management LP acquired a new stake in Pyxis Oncology in the 4th quarter valued at about $365,000. Graham Capital Management L.P. acquired a new stake in Pyxis Oncology in the 4th quarter valued at about $212,000. OMERS ADMINISTRATION Corp acquired a new stake in Pyxis Oncology in the 4th quarter valued at about $77,000. Finally, Barclays PLC lifted its holdings in Pyxis Oncology by 1,939.3% in the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock valued at $69,000 after acquiring an additional 57,424 shares during the last quarter. 39.07% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Price Performance

Shares of PYXS opened at $1.90 on Thursday. The company has a market capitalization of $120.37 million, a price-to-earnings ratio of -1.45 and a beta of 1.42. Pyxis Oncology, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $5.55. The business’s 50-day moving average is $1.87 and its 200-day moving average is $1.88.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Equities research analysts expect that Pyxis Oncology, Inc. will post -1.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Wedbush assumed coverage on Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Stifel Nicolaus cut their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings upgraded Pyxis Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 5th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average price target of $6.83.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.